Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa trial of NVG-222 in relapsed or refractory B-cell blood cancers
ISRCTN14974342Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of NVG-222 in hematopoietic malignancies, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS) and 9 more, sponsored by Cancer Research UK. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose / optimal biological dose / therapeutic dose range / optimal dose schedule and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
NVG-222
03
Conditions
hematopoietic malignancieschronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on ISRCTN14974342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14974342.